- Home
- GLDD vs TYRA Comparison
GLDD vs TYRA Comparison
Compare GLDD & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDD
- TYRA
- Stock Information
- Founded
- GLDD 1890
- TYRA 2018
- Country
- GLDD United States
- TYRA United States
- Employees
- GLDD N/A
- TYRA N/A
- Industry
- GLDD Military/Government/Technical
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- GLDD Industrials
- TYRA Health Care
- Exchange
- GLDD Nasdaq
- TYRA Nasdaq
- Market Cap
- GLDD 760.5M
- TYRA 812.7M
- IPO Year
- GLDD 2006
- TYRA 2021
- Fundamental
- Price
- GLDD $12.02
- TYRA $16.19
- Analyst Decision
- GLDD Buy
- TYRA Strong Buy
- Analyst Count
- GLDD 1
- TYRA 6
- Target Price
- GLDD $14.00
- TYRA $30.50
- AVG Volume (30 Days)
- GLDD 414.4K
- TYRA 265.8K
- Earning Date
- GLDD 02-12-2025
- TYRA 03-18-2025
- Dividend Yield
- GLDD N/A
- TYRA N/A
- EPS Growth
- GLDD N/A
- TYRA N/A
- EPS
- GLDD 0.87
- TYRA N/A
- Revenue
- GLDD $741,648,000.00
- TYRA N/A
- Revenue This Year
- GLDD $33.01
- TYRA N/A
- Revenue Next Year
- GLDD $6.88
- TYRA N/A
- P/E Ratio
- GLDD $13.77
- TYRA N/A
- Revenue Growth
- GLDD 33.74
- TYRA N/A
- 52 Week Low
- GLDD $6.55
- TYRA $12.34
- 52 Week High
- GLDD $12.89
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- GLDD 56.17
- TYRA 55.48
- Support Level
- GLDD $10.94
- TYRA $15.75
- Resistance Level
- GLDD $11.88
- TYRA $17.27
- Average True Range (ATR)
- GLDD 0.34
- TYRA 0.90
- MACD
- GLDD 0.08
- TYRA 0.25
- Stochastic Oscillator
- GLDD 83.08
- TYRA 72.99
About GLDD Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).